Find a Provider

Paul S. Wissel, MD

Paul S. Wissel, MD Physician

Adjunct Professor of Medicine

Dr. Wissel is a private practice physician who is not employed by Penn Medicine.

Clinical Specialties

Specialties:

  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Anal Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastrointestinal Carcinoid Tumor
    • Liver Cancer
    • Pancreatic Cancer
    • Rectal Cancer
    • Small Intestine Cancer
    • Stomach (Gastric) Cancer

Board Certification:

  • Internal Medicine, 1983
  • Medical Oncology, 2012

Conditions & Treatments:

  • Anal Cancer
  • Bile Duct Cancer
  • carcinoma - hepatocellular
  • clinical pharmacology
  • Colon Cancer
  • colorectal cancer
  • Esophageal Cancer
  • esophagogastric cancer
  • Gallbladder Cancer
  • gastrointestinal cancer
  • Gastrointestinal Carcinoid Tumor
  • Liver Tumor
  • Neuroendocrine Tumors
  • Pancreatic Cancer
  • pancreatic neuroendocrine
  • Rectal Cancer
  • Small Intestine Cancer
  • Stomach (Gastric) Cancer
  • stomach cancer
  • unknown primary cancer

Clinical Interests

Gastrointestinal tumors
Cancer of Unknown Primary
Clinical Pharmacology

Practice Locations and Appointments

  • Gastrointestinal Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Columbia University
Residency: Ohio State University Hospital
Residency: University of Cincinnati Medical Center
Fellowship: Memorial Sloan-Kettering Cancer Center

Memberships

American Association of Cancer Research, National American College of Clinical Pharmacology and Therapeutics, National American College of Physicians, National American Society of Clinical Oncology, National

Affiliation

Dr. Wissel is a private practice physician who is not employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

St├ęphane Temam, Anil D'Cruz, Minish Mahendra Jain, Ida D'Onofrio, Georgy M. Manikhas, Geza Horvai, Yan Sun, Stefan Dietzsch, Pavol Dubinsky, Petra Holeckova, Hisham Mehanna, Iman El-Hariry, Natalie Franklin, Nigel Biswas-Baldwin, Philippe Legenne, Paul Stephen Wissel, Thelma Netherway, Sergio Santillana, Jean Bourhis: Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). Kevin J. Harrington, Journal of Clinical Oncology 23 (6005): 2014.

Tudor-Eliade Ciuleanu, Igor Bazin, Dan Lungulescu, Lucian Miron, Igor Bondarenko, Andrzej Deptala, Maribel Rodriguez-Torres, Bruce J. Giantonio, Weijing Sun, Norma Lynn Fox, Gursel Aktan, Paul Stephen Wissel, Jacki Egger, Meichun Ding, Rubana Kalyani Matthew Joseph Gribbin;: Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology 32 (4029): 2014.

Bojana Milojkovic Kerklaan, Martijn P. J. K. Lolkema, Lot A. Devriese, Emile E. Voest, A. Nol-Boekel, M. Mergui-Roelvink, Kristine Mykulowycz, Joseph E Stoebenau, Lei Fang, Philippe Legenne, Paul Stephen Wissel, Deborah A. Smith, Bruce J. Giantonio, Jan HM Schellens, Petronella Witteveen: Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors. Journal of Clinical Oncology 31 (2536): 2013.

Rodryg Ramlau, Jacek Jassem, Zsolt Papai-Szekely, Pierre Chabot, Philippe Legenne, Jeremey Levin, Jadwiga Sherlock, Stephen R. Lane, John J Brennan, Tracey Sessa, Paul Stephen Wissel, Philip Bonomi: Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study Journal of Clinical Oncology 31 (2031): 2013.

Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Walter B. Roland, Rebecca L. Olin, Azra Raza, Aristotles Giagounidis, Oliver G. Ottmann, Aref Al-Kali, Elias J. Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, John Z. Zhu, Paul Wissel, and Hagop M. Kantarjian: Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease Blood 120 (677): 2012.

Sohal D., Teitelbaum U., Uehara T., Mykulowycz K., Watt C.D., Damjanov N., Giantonio B., Carberry M., Wissel P., Jacobs-Small M., O'Dwyer P., Sun W., Sepulveda A.R. and Sun W.: Mutational analysis of EGFR, KRAS and BRAF in advanced cholangiocarcinoma and association with clinical outcomes - An interim report of a phase II trial Journal of Molecular Diagnostics : 2012.

Grunberg, Steven M. Rolski, Janusz. Strausz, Janos. Aziz, Zeba. Lane, Stephen. Russo, Mark W. Wissel, Paul. Guckert, Mary. Wright, Oliver. Herrstedt, Jorn.: Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncology 10 (6): 549-58,2009.

Fields, Anthony L A. Keller, Alan. Schwartzberg, Lee. Bernard, Stephen. Kardinal, Carl. Cohen, Alan. Schulz, Joe. Eisenberg, Peter. Forster, John. Wissel, Paul.: Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. Journal of Clinical Oncology 27 (12): 1941-7,2009.

Lilenbaum, Rogerio C. Huber, Rudolf M. Treat, Joseph. Masters, Gregory. Kaubitzsch, Sabine. Lane, Stephen. Wissel, Paul.: Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status. Clinical Lung Cancer 8 (2): 130-4,2006.

Eckardt, John R. von Pawel, Joachim. Papai, Zsolt. Tomova, Antoaneta. Tzekova, Valentina. Crofts, Theresa E. Brannon, Sarah. Wissel, Paul. Ross, Graham.: Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Journal of Clinical Oncology 24 (13): 2044-51,2006.

Academic Contact Info

Abramson Cancer Center
University of Pennsylvania
Division of Hematology/Oncology
16 Penn Tower
300 South 33rd Street
Philadelphia PA, 19104

Philadelphia, PA 19104
Phone: (215) 662-7606
Fax: (215) 349-8551
Patient appointments: 800-789-PENN (7366)

Related Links